Lars Norgren, Norbert Weiss, Sigrid Nikol, John C Lantis, Manesh R Patel, Robert J Hinchliffe, Holger Reinecke, Hans Dieter Volk, Petra Reinke, Gian Paolo Fadini, Racheli Ofir, Daniel Rothenstein, Nitsan Halevy, Mitko Karagjozov, John H Rundback
BACKGROUND: Revascularization is the primary treatment modality for chronic limb-threatening ischaemia (CLTI), but is not feasible in all patients. PLX-PAD is an off-the-shelf, placental-derived, mesenchymal stromal cell-like cell therapy. This study aimed to evaluate whether PLX-PAD would increase amputation-free survival in people with CLTI who were not candidates for revascularization. METHODS: People with CLTI and minor tissue loss (Rutherford 5) who were unsuitable for revascularization were entered into a randomized, parallel-group, placebo-controlled, multinational, blinded, trial, in which PLX-PAD was compared with placebo (2 : 1 randomization), with 30 intramuscular injections (0...
January 31, 2024: British Journal of Surgery